expert report on survival data from pivotal trials with parp inhibitors for brca-mut. ovarian cancer
Published 1 year ago • 1.4K plays • Length 4:44Download video MP4
Download video MP3
Similar videos
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
3:45
parp inhibitors for ovarian cancer
-
4:58
expert report on neoadjuvant immune checkpoint inhibitors for melanoma
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
5:30
expert report on immune checkpoint inhibitors for dmmr colorectal cancer
-
7:00
expert report on neoadjuvant immune checkpoint inhibitors for nsclc
-
4:33
how to determine best first line treatment for ovarian cancer?
-
1:13
final os results from paola-1 evaluating 1l maintenance olaparib plus bevacizumab
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
1:41
parp inhibitors at the crossroads in ovarian cancer: 2022 esmo florida
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:58
solo-1: practice changing data on olaparib for ovarian cancer
-
1:38
updates in parp inhibition for ovarian cancer
-
1:43
esmo virtual plenaries: why you should not miss these presentations of new oncology data
-
2:11
long-term benefit from 1l maintenance parp inhibitors in ovarian cancer
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
2:27
the paola-1 study: olaparib and bevacizumab for ovarian cancer